• Clover Biopharma adds $230M as Covid-19 vaccine heads to pivotal test

    11 days ago - By MedCity News

    The protein-based Covid-19 vaccine from Clover Biopharmaceuticals has distribution and storage advantages compared to messenger RNA vaccines. If the vaccine succeeds in a Phase 2/3 test, China-based Clover will distribute it globally via COVAX.
    Read more ...

     

  • RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing

    RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing

    11 days ago - By NIBIB / NIH

    RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing
    NIBIB in the News coneyjohnsons
    Tue, 02/23/2021 - 09:43
    The final RADx portfolio of products to be developed and scaled includes a diversity of diagnostics from companies such as Illumina, Quidel, Fluidigm, and Mesa Biotech, and is likely to result in a near-term manufacturing boom in rapid antigen tests and over-the-counter home-use diagnostics.
    Read more ...